Please use this identifier to cite or link to this item: https://doi.org/10.1097/FPC.0b013e32834a8639
Title: Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer
Authors: Wong, N.-S.
Seah, E.Z.H.
Wang, L.-Z.
Yeo, W.-L. 
Yap, H.-L.
Chuah, B.
Lim, Y.-W.
Ang, P.C.S.
Tai, B.-C. 
Lim, R.
Goh, B.-C.
Lee, S.-C. 
Keywords: breast cancer
pharmacogenetics
UGT2B17
UGT2B17 2
vorinostat
Issue Date: Nov-2011
Citation: Wong, N.-S., Seah, E.Z.H., Wang, L.-Z., Yeo, W.-L., Yap, H.-L., Chuah, B., Lim, Y.-W., Ang, P.C.S., Tai, B.-C., Lim, R., Goh, B.-C., Lee, S.-C. (2011-11). Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenetics and Genomics 21 (11) : 760-768. ScholarBank@NUS Repository. https://doi.org/10.1097/FPC.0b013e32834a8639
Abstract: OBJECTIVES: Vorinostat, a histone deacetylase inhibitor being actively evaluated in solid tumors, is metabolized by UGT2B17. UGT2B17 null genotype (UGT2B17*2) has been shown in vitro to reduce UGT2B17 activity. This variant is common in Asians but rare in Caucasians, and we studied its impact on vorinostat pharmacokinetics and pharmacodynamics in a clinical study in Asian patients with metastatic breast cancer. METHODS: Eligible patients received 400 mg of vorinostat monotherapy daily in a lead-in phase I followed by a phase II study. Patients were genotyped for UGT2B17*2, which was correlated with vorinostat pharmacokinetics and clinical outcomes. Results: Twenty-six patients were treated with no complete response, one partial response, six stable disease lasting for 12 weeks or more, and 19 progressive disease. Sixteen patients (62%) were UGT2B17*2 homozygotes and had significantly lower mean area under the curve ratio of vorinostat-O-glucuronide/vorinostat (1.84 vs. 2.51 on day 1, P=0.02; 1.63 vs. 2.38 on day 15, P=0.028), and trended toward having higher vorinostat area under the curve (399.02 vs. 318.40, P=0.188), more serious adverse events (31 vs. 0%, P=0.121), higher clinical benefit rate (40 vs. 10%, P=0.179), and longer median progression-free survival (3.0 vs. 1.5 months, P=0.087) than patients with at least one wild-type allele. Conclusion: UGT2B17*2 genotype reduces vorinostat glucuronidation and may increase vorinostat efficacy and toxicity. These observations are important in the development of vorinostat, and may have clinical implications on other cancer and noncancer drugs that are UGT2B17 substrates such as exemestane and ibuprofen. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Source Title: Pharmacogenetics and Genomics
URI: http://scholarbank.nus.edu.sg/handle/10635/109400
ISSN: 17446872
DOI: 10.1097/FPC.0b013e32834a8639
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

25
checked on Sep 16, 2019

WEB OF SCIENCETM
Citations

23
checked on Sep 9, 2019

Page view(s)

72
checked on Sep 7, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.